Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients
Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term surviva...
Ausführliche Beschreibung
Autor*in: |
Fabian Doerr [verfasserIn] Tobias Leschczyk [verfasserIn] Konstantinos Grapatsas [verfasserIn] Hruy Menghesha [verfasserIn] Natalie Baldes [verfasserIn] Georg Schlachtenberger [verfasserIn] Matthias B. Heldwein [verfasserIn] Maximilian Michel [verfasserIn] Alexander Quaas [verfasserIn] Lars Hagmeyer [verfasserIn] Katja Höpker [verfasserIn] Thorsten Wahlers [verfasserIn] Kaid Darwiche [verfasserIn] Christian Taube [verfasserIn] Martin Schuler [verfasserIn] Khosro Hekmat [verfasserIn] Servet Bölükbas [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2024 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Cancers - MDPI AG, 2010, 16(2024), 2, p 465 |
---|---|
Übergeordnetes Werk: |
volume:16 ; year:2024 ; number:2, p 465 |
Links: |
---|
DOI / URN: |
10.3390/cancers16020465 |
---|
Katalog-ID: |
DOAJ096382678 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ096382678 | ||
003 | DE-627 | ||
005 | 20240413150857.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240413s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/cancers16020465 |2 doi | |
035 | |a (DE-627)DOAJ096382678 | ||
035 | |a (DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC254-282 | |
100 | 0 | |a Fabian Doerr |e verfasserin |4 aut | |
245 | 1 | 0 | |a Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. | ||
650 | 4 | |a non-small-cell lung cancer | |
650 | 4 | |a lobectomy | |
650 | 4 | |a lung capacity | |
650 | 4 | |a life quality | |
650 | 4 | |a long-term survival | |
650 | 4 | |a smoking cessation | |
653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
700 | 0 | |a Tobias Leschczyk |e verfasserin |4 aut | |
700 | 0 | |a Konstantinos Grapatsas |e verfasserin |4 aut | |
700 | 0 | |a Hruy Menghesha |e verfasserin |4 aut | |
700 | 0 | |a Natalie Baldes |e verfasserin |4 aut | |
700 | 0 | |a Georg Schlachtenberger |e verfasserin |4 aut | |
700 | 0 | |a Matthias B. Heldwein |e verfasserin |4 aut | |
700 | 0 | |a Maximilian Michel |e verfasserin |4 aut | |
700 | 0 | |a Alexander Quaas |e verfasserin |4 aut | |
700 | 0 | |a Lars Hagmeyer |e verfasserin |4 aut | |
700 | 0 | |a Katja Höpker |e verfasserin |4 aut | |
700 | 0 | |a Thorsten Wahlers |e verfasserin |4 aut | |
700 | 0 | |a Kaid Darwiche |e verfasserin |4 aut | |
700 | 0 | |a Christian Taube |e verfasserin |4 aut | |
700 | 0 | |a Martin Schuler |e verfasserin |4 aut | |
700 | 0 | |a Khosro Hekmat |e verfasserin |4 aut | |
700 | 0 | |a Servet Bölükbas |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Cancers |d MDPI AG, 2010 |g 16(2024), 2, p 465 |w (DE-627)614095670 |w (DE-600)2527080-1 |x 20726694 |7 nnns |
773 | 1 | 8 | |g volume:16 |g year:2024 |g number:2, p 465 |
856 | 4 | 0 | |u https://doi.org/10.3390/cancers16020465 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c |z kostenfrei |
856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/16/2/465 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2072-6694 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 16 |j 2024 |e 2, p 465 |
author_variant |
f d fd t l tl k g kg h m hm n b nb g s gs m b h mbh m m mm a q aq l h lh k h kh t w tw k d kd c t ct m s ms k h kh s b sb |
---|---|
matchkey_str |
article:20726694:2024----::otprtvtbcoestoipoeqaiyfieugucinnlntrsriain |
hierarchy_sort_str |
2024 |
callnumber-subject-code |
RC |
publishDate |
2024 |
allfields |
10.3390/cancers16020465 doi (DE-627)DOAJ096382678 (DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c DE-627 ger DE-627 rakwb eng RC254-282 Fabian Doerr verfasserin aut Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. non-small-cell lung cancer lobectomy lung capacity life quality long-term survival smoking cessation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tobias Leschczyk verfasserin aut Konstantinos Grapatsas verfasserin aut Hruy Menghesha verfasserin aut Natalie Baldes verfasserin aut Georg Schlachtenberger verfasserin aut Matthias B. Heldwein verfasserin aut Maximilian Michel verfasserin aut Alexander Quaas verfasserin aut Lars Hagmeyer verfasserin aut Katja Höpker verfasserin aut Thorsten Wahlers verfasserin aut Kaid Darwiche verfasserin aut Christian Taube verfasserin aut Martin Schuler verfasserin aut Khosro Hekmat verfasserin aut Servet Bölükbas verfasserin aut In Cancers MDPI AG, 2010 16(2024), 2, p 465 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:16 year:2024 number:2, p 465 https://doi.org/10.3390/cancers16020465 kostenfrei https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c kostenfrei https://www.mdpi.com/2072-6694/16/2/465 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2024 2, p 465 |
spelling |
10.3390/cancers16020465 doi (DE-627)DOAJ096382678 (DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c DE-627 ger DE-627 rakwb eng RC254-282 Fabian Doerr verfasserin aut Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. non-small-cell lung cancer lobectomy lung capacity life quality long-term survival smoking cessation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tobias Leschczyk verfasserin aut Konstantinos Grapatsas verfasserin aut Hruy Menghesha verfasserin aut Natalie Baldes verfasserin aut Georg Schlachtenberger verfasserin aut Matthias B. Heldwein verfasserin aut Maximilian Michel verfasserin aut Alexander Quaas verfasserin aut Lars Hagmeyer verfasserin aut Katja Höpker verfasserin aut Thorsten Wahlers verfasserin aut Kaid Darwiche verfasserin aut Christian Taube verfasserin aut Martin Schuler verfasserin aut Khosro Hekmat verfasserin aut Servet Bölükbas verfasserin aut In Cancers MDPI AG, 2010 16(2024), 2, p 465 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:16 year:2024 number:2, p 465 https://doi.org/10.3390/cancers16020465 kostenfrei https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c kostenfrei https://www.mdpi.com/2072-6694/16/2/465 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2024 2, p 465 |
allfields_unstemmed |
10.3390/cancers16020465 doi (DE-627)DOAJ096382678 (DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c DE-627 ger DE-627 rakwb eng RC254-282 Fabian Doerr verfasserin aut Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. non-small-cell lung cancer lobectomy lung capacity life quality long-term survival smoking cessation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tobias Leschczyk verfasserin aut Konstantinos Grapatsas verfasserin aut Hruy Menghesha verfasserin aut Natalie Baldes verfasserin aut Georg Schlachtenberger verfasserin aut Matthias B. Heldwein verfasserin aut Maximilian Michel verfasserin aut Alexander Quaas verfasserin aut Lars Hagmeyer verfasserin aut Katja Höpker verfasserin aut Thorsten Wahlers verfasserin aut Kaid Darwiche verfasserin aut Christian Taube verfasserin aut Martin Schuler verfasserin aut Khosro Hekmat verfasserin aut Servet Bölükbas verfasserin aut In Cancers MDPI AG, 2010 16(2024), 2, p 465 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:16 year:2024 number:2, p 465 https://doi.org/10.3390/cancers16020465 kostenfrei https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c kostenfrei https://www.mdpi.com/2072-6694/16/2/465 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2024 2, p 465 |
allfieldsGer |
10.3390/cancers16020465 doi (DE-627)DOAJ096382678 (DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c DE-627 ger DE-627 rakwb eng RC254-282 Fabian Doerr verfasserin aut Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. non-small-cell lung cancer lobectomy lung capacity life quality long-term survival smoking cessation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tobias Leschczyk verfasserin aut Konstantinos Grapatsas verfasserin aut Hruy Menghesha verfasserin aut Natalie Baldes verfasserin aut Georg Schlachtenberger verfasserin aut Matthias B. Heldwein verfasserin aut Maximilian Michel verfasserin aut Alexander Quaas verfasserin aut Lars Hagmeyer verfasserin aut Katja Höpker verfasserin aut Thorsten Wahlers verfasserin aut Kaid Darwiche verfasserin aut Christian Taube verfasserin aut Martin Schuler verfasserin aut Khosro Hekmat verfasserin aut Servet Bölükbas verfasserin aut In Cancers MDPI AG, 2010 16(2024), 2, p 465 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:16 year:2024 number:2, p 465 https://doi.org/10.3390/cancers16020465 kostenfrei https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c kostenfrei https://www.mdpi.com/2072-6694/16/2/465 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2024 2, p 465 |
allfieldsSound |
10.3390/cancers16020465 doi (DE-627)DOAJ096382678 (DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c DE-627 ger DE-627 rakwb eng RC254-282 Fabian Doerr verfasserin aut Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. non-small-cell lung cancer lobectomy lung capacity life quality long-term survival smoking cessation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tobias Leschczyk verfasserin aut Konstantinos Grapatsas verfasserin aut Hruy Menghesha verfasserin aut Natalie Baldes verfasserin aut Georg Schlachtenberger verfasserin aut Matthias B. Heldwein verfasserin aut Maximilian Michel verfasserin aut Alexander Quaas verfasserin aut Lars Hagmeyer verfasserin aut Katja Höpker verfasserin aut Thorsten Wahlers verfasserin aut Kaid Darwiche verfasserin aut Christian Taube verfasserin aut Martin Schuler verfasserin aut Khosro Hekmat verfasserin aut Servet Bölükbas verfasserin aut In Cancers MDPI AG, 2010 16(2024), 2, p 465 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:16 year:2024 number:2, p 465 https://doi.org/10.3390/cancers16020465 kostenfrei https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c kostenfrei https://www.mdpi.com/2072-6694/16/2/465 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2024 2, p 465 |
language |
English |
source |
In Cancers 16(2024), 2, p 465 volume:16 year:2024 number:2, p 465 |
sourceStr |
In Cancers 16(2024), 2, p 465 volume:16 year:2024 number:2, p 465 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
non-small-cell lung cancer lobectomy lung capacity life quality long-term survival smoking cessation Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
isfreeaccess_bool |
true |
container_title |
Cancers |
authorswithroles_txt_mv |
Fabian Doerr @@aut@@ Tobias Leschczyk @@aut@@ Konstantinos Grapatsas @@aut@@ Hruy Menghesha @@aut@@ Natalie Baldes @@aut@@ Georg Schlachtenberger @@aut@@ Matthias B. Heldwein @@aut@@ Maximilian Michel @@aut@@ Alexander Quaas @@aut@@ Lars Hagmeyer @@aut@@ Katja Höpker @@aut@@ Thorsten Wahlers @@aut@@ Kaid Darwiche @@aut@@ Christian Taube @@aut@@ Martin Schuler @@aut@@ Khosro Hekmat @@aut@@ Servet Bölükbas @@aut@@ |
publishDateDaySort_date |
2024-01-01T00:00:00Z |
hierarchy_top_id |
614095670 |
id |
DOAJ096382678 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ096382678</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413150857.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers16020465</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ096382678</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Fabian Doerr</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">non-small-cell lung cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lobectomy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lung capacity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">life quality</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">long-term survival</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">smoking cessation</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tobias Leschczyk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Konstantinos Grapatsas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hruy Menghesha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natalie Baldes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Georg Schlachtenberger</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matthias B. Heldwein</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maximilian Michel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexander Quaas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lars Hagmeyer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katja Höpker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thorsten Wahlers</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kaid Darwiche</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christian Taube</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martin Schuler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Khosro Hekmat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Servet Bölükbas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">16(2024), 2, p 465</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:2, p 465</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers16020465</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/16/2/465</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2024</subfield><subfield code="e">2, p 465</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Fabian Doerr |
spellingShingle |
Fabian Doerr misc RC254-282 misc non-small-cell lung cancer misc lobectomy misc lung capacity misc life quality misc long-term survival misc smoking cessation misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients |
authorStr |
Fabian Doerr |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)614095670 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC254-282 |
illustrated |
Not Illustrated |
issn |
20726694 |
topic_title |
RC254-282 Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients non-small-cell lung cancer lobectomy lung capacity life quality long-term survival smoking cessation |
topic |
misc RC254-282 misc non-small-cell lung cancer misc lobectomy misc lung capacity misc life quality misc long-term survival misc smoking cessation misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
topic_unstemmed |
misc RC254-282 misc non-small-cell lung cancer misc lobectomy misc lung capacity misc life quality misc long-term survival misc smoking cessation misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
topic_browse |
misc RC254-282 misc non-small-cell lung cancer misc lobectomy misc lung capacity misc life quality misc long-term survival misc smoking cessation misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Cancers |
hierarchy_parent_id |
614095670 |
hierarchy_top_title |
Cancers |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)614095670 (DE-600)2527080-1 |
title |
Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients |
ctrlnum |
(DE-627)DOAJ096382678 (DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c |
title_full |
Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients |
author_sort |
Fabian Doerr |
journal |
Cancers |
journalStr |
Cancers |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2024 |
contenttype_str_mv |
txt |
author_browse |
Fabian Doerr Tobias Leschczyk Konstantinos Grapatsas Hruy Menghesha Natalie Baldes Georg Schlachtenberger Matthias B. Heldwein Maximilian Michel Alexander Quaas Lars Hagmeyer Katja Höpker Thorsten Wahlers Kaid Darwiche Christian Taube Martin Schuler Khosro Hekmat Servet Bölükbas |
container_volume |
16 |
class |
RC254-282 |
format_se |
Elektronische Aufsätze |
author-letter |
Fabian Doerr |
doi_str_mv |
10.3390/cancers16020465 |
author2-role |
verfasserin |
title_sort |
postoperative tobacco cessation improves quality of life, lung function and long-term survival in non-small-cell lung cancer patients |
callnumber |
RC254-282 |
title_auth |
Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients |
abstract |
Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. |
abstractGer |
Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. |
abstract_unstemmed |
Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
2, p 465 |
title_short |
Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients |
url |
https://doi.org/10.3390/cancers16020465 https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c https://www.mdpi.com/2072-6694/16/2/465 https://doaj.org/toc/2072-6694 |
remote_bool |
true |
author2 |
Tobias Leschczyk Konstantinos Grapatsas Hruy Menghesha Natalie Baldes Georg Schlachtenberger Matthias B. Heldwein Maximilian Michel Alexander Quaas Lars Hagmeyer Katja Höpker Thorsten Wahlers Kaid Darwiche Christian Taube Martin Schuler Khosro Hekmat Servet Bölükbas |
author2Str |
Tobias Leschczyk Konstantinos Grapatsas Hruy Menghesha Natalie Baldes Georg Schlachtenberger Matthias B. Heldwein Maximilian Michel Alexander Quaas Lars Hagmeyer Katja Höpker Thorsten Wahlers Kaid Darwiche Christian Taube Martin Schuler Khosro Hekmat Servet Bölükbas |
ppnlink |
614095670 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.3390/cancers16020465 |
callnumber-a |
RC254-282 |
up_date |
2024-07-03T19:51:54.779Z |
_version_ |
1803588798810947584 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ096382678</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413150857.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers16020465</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ096382678</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJbb6ffe19ca394940851f9cec4f51c84c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Fabian Doerr</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives: About 90% of all non-small cell lung cancer (NSCLC) cases are associated with inhalative tabacco smoking. Half of patients continue smoking during lung cancer therapy. We examined the effects of postoperative smoking cessation on lung function, quality of life (QOL) and long-term survival. Materials and Methods: In total, 641 patients, who underwent lobectomy between 2012 and 2019, were identified from our single institutional data base. Postoperatively, patients that actively smoked at the time of operation were offered a structured ‘smoking cessation’ program. For this retrospective analysis, two patient groups (total <i<n</i< = 90) were selected by pair matching. Group A (<i<n</i< = 60) had no postoperative tobacco smoking. Group B (<i<n</i< = 30) involved postoperative continued smoking. Lung function (FEV1, DLCO) and QOL (‘SF-36′ questionnaire) were measured 12 months postoperatively. We compared long-term outcomes using Kaplan–Meier curves. Results: The mean age in group A was 62.6 ± 12.5 years and that in group B was 64.3 ± 9.7 years (<i<p</i< = 0.82); 64% and 62%, respectively, were male (<i<p</i< = 0.46). Preoperative smoking habits were similar (‘pack years’: group A, 47 ± 31; group B, 49 ± 27; <i<p</i< = 0.87). All relevant baseline characteristics we collected were similar (<i<p</i< < 0.05). One year after lobectomy, FEV1 was reduced by 15% in both groups (<i<p</i< = 0.98). Smoking cessation was significantly associated with improved DLCO (group A: 11 ± 16%; group B: −5 ± 14%; <i<p</i< <0.001) and QOL (vitality (VT): +10 vs. −10, <i<p</i< = 0.017; physical role function (RP): +8 vs. −17, <i<p</i< = 0.012; general health perceptions (GH): +12 vs. −5, <i<p</i< = 0.024). Patients who stopped smoking postoperatively had a significantly superior overall survival (median survival: 89.8 ± 6.8 [95% CI: 76.6–103.1] months vs. 73.9 ± 3.6 [95% CI: 66.9–80.9] months, <i<p</i< = 0.034; 3-year OS rate: 96.2% vs. 81.0%, <i<p</i< = 0.02; 5-year OS rate: 80.0% vs. 64.0%, <i<p</i< = 0.016). The hazard ratio (HR) was 2.31 [95% CI: 1.04–5.13] for postoperative smoking versus tobacco cessation. Conclusion: Postoperative smoking cessation is associated with improved quality of life and lung function testing. Notably, a significant increase in long-term survival rates among non-smoking NSCLC patients was observed. These findings could serve as motivation for patients to successfully complete a non-smoking program.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">non-small-cell lung cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lobectomy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lung capacity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">life quality</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">long-term survival</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">smoking cessation</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tobias Leschczyk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Konstantinos Grapatsas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hruy Menghesha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natalie Baldes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Georg Schlachtenberger</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matthias B. Heldwein</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maximilian Michel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexander Quaas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lars Hagmeyer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katja Höpker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thorsten Wahlers</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kaid Darwiche</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christian Taube</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martin Schuler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Khosro Hekmat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Servet Bölükbas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">16(2024), 2, p 465</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:2, p 465</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers16020465</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/bb6ffe19ca394940851f9cec4f51c84c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/16/2/465</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2024</subfield><subfield code="e">2, p 465</subfield></datafield></record></collection>
|
score |
7.3998823 |